By E-commerce 4 Internet Marketers Editorial
Explainer. This article summarizes U.S. Food and Drug Administration reminders for telehealth companies that promote compounded drugs on websites, with a focus on claim patterns FDA lists as false or misleading. Facts are drawn from FDA's page FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. Website owners, developers, and operators who sell or market compounded GLP-1 offers and other compounded products should treat promotional copy as a compliance surface, not a conversion afterthought. This is not legal advice. Confirm live site claims with counsel against FDA's published reminder and related enforcement materials.
Why this guidance matters for telehealth storefronts
FDA says it is concerned about telehealth companies promoting compounded drugs, including glucagon-like peptide-1 receptor agonists (GLP-1s) and other drugs, with false or misleading claims. The agency states that those claims put patients at risk because they cannot make an informed health decision, and that the conduct also violates federal law.
For high-risk ecommerce teams, the practical point is narrower and operational. Homepage banners, product detail pages, FAQ copy, checkout scripts, email, and paid ads that blur the line between compounded products and FDA-approved drugs are exactly the surfaces FDA is watching. Marketing that overstates approval status or sameness is not only a patient-communication problem. It is a regulatory and acquiring-risk signal when the catalog is telehealth, compounded, and sold online.
FDA also states that it has issued warning letters to telehealth companies over false or misleading claims. The agency directs readers to search the term “telehealth” in its warning letter database to find those letters. This explainer does not invent recipient lists, letter dates, or molecule-specific allegations beyond what the guidance page itself states.
Five promotion patterns FDA tells telehealth companies to avoid
FDA reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims. The guidance page lists five patterns. The list below stays inside that page. It does not add extra legal tests or “safe harbor” wording FDA did not publish there.
1. Branding that implies the telehealth company is the compounder
Do not use website branding that falsely or misleadingly implies the telehealth company is the compounder. On a storefront, that often shows up as private-label product titles, vial or carton imagery, or hero copy that presents the telehealth DBA as the manufacturing source when the product is compounded elsewhere. FDA's reminder treats that implication as a false or misleading claim pattern.
2. Generic or “same as FDA-approved” descriptions
Do not describe a compounded drug as a generic version of an FDA-approved drug, or as the same as a drug approved by FDA. FDA states that generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA. Operators who reuse “generic,” “same as,” or parallel brand-name comparisons in PDP titles and FAQ answers are writing directly into this reminder.
3. FDA-approved or safety and effectiveness evaluation claims
Do not claim a compounded drug has been FDA-approved, or that it has otherwise been evaluated for safety and effectiveness, when that is not true. FDA states that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality prior to marketing. Trust badges, footer seals, and checkout microcopy that imply FDA product review for a compounded offer conflict with this reminder.
4. “Clinically proven” sameness of results
Do not describe a compounded drug as clinically proven to produce the same result as the FDA-approved drug. Outcome-equivalence language on landing pages and retargeting creatives is a common conversion shortcut. FDA lists it among the false or misleading claim patterns telehealth companies should not use.
5. “FDA-approved” or “FDA-licensed” pharmacy or facility sourcing claims
Do not claim a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA states that it does not approve or license any facility. Sourcing claims that dress a compounding pharmacy or outsourcing facility in “FDA-approved” or “FDA-licensed” language conflict with this reminder, even when the operator believes the pharmacy is otherwise regulated under other frameworks.
What FDA says it will keep doing
FDA states that it remains vigilant in its oversight of promotional materials and will continue to take actions to help protect patients from false or misleading claims by telehealth companies. The guidance page does not spell out response deadlines, fine schedules, or a checklist of “approved” alternative marketing language. This article therefore does not invent those details.
How website and payments teams should use the reminder
Map the five patterns to every claim surface that ships with the storefront:
- Product and landing pages that call compounded offers generic, FDA-approved, or “the same as” an approved brand
- Telehealth branding on vials, cartons, or PDP titles that imply the telehealth firm is the compounder
- FAQ, SMS, and checkout copy that says the product was evaluated for safety and effectiveness by FDA
- Creative that calls outcomes “clinically proven” to match an FDA-approved drug
- Sourcing statements that call a pharmacy or outsourcing facility “FDA-approved” or “FDA-licensed”
Engineering and growth teams should also pull live warning letters with the “telehealth” search term FDA recommends, then compare letter language to current site modules rather than relying on secondary roundups. Payment and underwriting partners often ask for the same claim inventory when compounded weight-loss or telehealth catalogs appear in disputes or MID reviews.
This explainer stays inside FDA's published reminder. It does not invent compounding eligibility rules, Section 503A or 503B operating requirements, cure periods, or "compliant" substitute claims that the guidance page does not provide. Counsel should review live promotional materials against FDA's published reminder and any related warning letters.